EA199800177A1 - A method of reducing the amount of exogenous insulin administered to a patient having noninsulin-dependent diabetes mellitus - Google Patents

A method of reducing the amount of exogenous insulin administered to a patient having noninsulin-dependent diabetes mellitus

Info

Publication number
EA199800177A1
EA199800177A1 EA199800177A EA199800177A EA199800177A1 EA 199800177 A1 EA199800177 A1 EA 199800177A1 EA 199800177 A EA199800177 A EA 199800177A EA 199800177 A EA199800177 A EA 199800177A EA 199800177 A1 EA199800177 A1 EA 199800177A1
Authority
EA
Eurasian Patent Office
Prior art keywords
patient
diabetes mellitus
reducing
dependent diabetes
noninsulin
Prior art date
Application number
EA199800177A
Other languages
Russian (ru)
Inventor
Рэндал В. Уиткомб
Original Assignee
Варнер-Ламберт Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Варнер-Ламберт Компани filed Critical Варнер-Ламберт Компани
Publication of EA199800177A1 publication Critical patent/EA199800177A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Изобретение обеспечивает способ снижения экзогенного инсулина, вводимого пациенту с инсулиннезависимым сахарным диабетом, состоящий в том, что пациенту вводят терапевтически эффективное количество производного тиазолидиона и/или родственных соединений.Международная заявка была опубликована вместе с отчетом о международном поиске.The invention provides a method for reducing exogenous insulin administered to a patient with non-insulin-dependent diabetes mellitus, comprising administering to the patient a therapeutically effective amount of a thiazolidione derivative and / or related compounds. An international application has been published together with an international search report.

EA199800177A 1995-08-10 1996-07-29 A method of reducing the amount of exogenous insulin administered to a patient having noninsulin-dependent diabetes mellitus EA199800177A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US209895P 1995-08-10 1995-08-10
PCT/US1996/012430 WO1997005875A2 (en) 1995-08-10 1996-07-29 A method of reducing the amount of exogenous insulin administered to a patient having noninsulin-dependent diabetes mellitus

Publications (1)

Publication Number Publication Date
EA199800177A1 true EA199800177A1 (en) 1998-10-29

Family

ID=21699238

Family Applications (1)

Application Number Title Priority Date Filing Date
EA199800177A EA199800177A1 (en) 1995-08-10 1996-07-29 A method of reducing the amount of exogenous insulin administered to a patient having noninsulin-dependent diabetes mellitus

Country Status (15)

Country Link
EP (1) EP0851757A2 (en)
JP (1) JPH11510508A (en)
KR (1) KR19990036290A (en)
CN (1) CN1192683A (en)
AU (1) AU724989B2 (en)
BG (1) BG102235A (en)
CA (1) CA2221241A1 (en)
CZ (1) CZ32998A3 (en)
EA (1) EA199800177A1 (en)
HU (1) HUP9802543A2 (en)
IL (1) IL122191A0 (en)
NO (1) NO980556D0 (en)
NZ (1) NZ313874A (en)
SK (1) SK16498A3 (en)
WO (1) WO1997005875A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9711683D0 (en) * 1997-06-05 1997-08-06 Smithkline Beecham Plc Composition
GB9712866D0 (en) * 1997-06-18 1997-08-20 Smithkline Beecham Plc Novel method of treatment
GB2335597A (en) * 1998-03-27 1999-09-29 Glaxo Group Ltd Stereoisomers of Troglitazone in the Treatment of Diabetes
FR2838968A1 (en) * 2002-04-30 2003-10-31 Lipha ASSOCIATION OF INSULIN AND A THIAZOLIDINEDIONE DERIVATIVE AND USE THEREOF FOR TREATING DIABETES

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6051189A (en) * 1983-08-30 1985-03-22 Sankyo Co Ltd Thiazolidine derivative and its preparation
US4873255A (en) * 1987-02-04 1989-10-10 Sankyo Company Limited Thiazolidinone derivatives, their preparation and their use
US5478852C1 (en) * 1993-09-15 2001-03-13 Sankyo Co Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of impaired glucose tolerance in order to prevent or delay the onset of noninsulin-dependent diabetes mellitus
TWI238064B (en) 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes

Also Published As

Publication number Publication date
AU6641196A (en) 1997-03-05
IL122191A0 (en) 1998-04-05
CN1192683A (en) 1998-09-09
EP0851757A2 (en) 1998-07-08
NZ313874A (en) 2000-09-29
JPH11510508A (en) 1999-09-14
BG102235A (en) 1998-09-30
WO1997005875A2 (en) 1997-02-20
NO980556L (en) 1998-02-09
HUP9802543A2 (en) 1999-07-28
CZ32998A3 (en) 1998-10-14
AU724989B2 (en) 2000-10-05
WO1997005875A3 (en) 1997-03-27
SK16498A3 (en) 1999-03-12
KR19990036290A (en) 1999-05-25
CA2221241A1 (en) 1997-02-20
NO980556D0 (en) 1998-02-09

Similar Documents

Publication Publication Date Title
EA200000041A1 (en) METHOD OF TREATMENT OF DIABETES THIAZOLIDINDIONE AND METHORMIN
ES2187659T3 (en) TREATMENT OF TYPE II MELLITUS DIABETES WITH AMILINA AGONISTS.
FI842915A0 (en) PHARMACEUTICAL MEDIA FOR BEHANDLING AV DIABETES.
KR930702022A (en) Treatment or prevention of type 1 diabetes by oral administration of insulin
RU94041223A (en) Agent for motoneuron disease treatment
HUP9800523A2 (en) Insulin derivatives
ITBO950533A0 (en) SYRINGE FOR HYPODERMIC INJECTIONS.
EA199800717A1 (en) METHOD FOR THE TREATMENT OF MAMMAL DISEASES AND THE CYVITTERION COMPOSITION
CA2047903A1 (en) Calcitonin-containing emulsion for nasal administration
EA200000139A1 (en) TREATMENT OF DIABETES THIAZOLIDINDIONON, MEANS, INCENTIVE INSULIN SECRETION, AND DIGUANIDE
ES2131122T3 (en) USE OF IL-10 TO PREVENT INSULIN DEPENDENT DIABETES MELLITUS.
KR920002151A (en) Inflammatory Disease Treatment with 15-Keto-Prostaglandin Compounds
BR9810444A (en) Treatment of diabetes with rosiglitazone and insulin
EA199800177A1 (en) A method of reducing the amount of exogenous insulin administered to a patient having noninsulin-dependent diabetes mellitus
CO4940452A1 (en) CRYSTAL MODIFICATION OF AN ACTIVE MEDICINAL SUBSTANCE
AU1081695A (en) The use of an ester of inositoltrisphosphate for the preparing of medicaments
EA199900881A1 (en) THERAPEUTICALLY AGAINST DIABETIC DIABETES
ES2181923T3 (en) 4-HYDROXICUMARIN-3-CARBOXAMIDES FOR THE TREATMENT OF DIABET IS MELLITUS NOT INSULIN DEPENDENT.
ES2113345T3 (en) TREATMENT OF CARDIAC DYSFUNCTION WITH THE HELP OF COMPOUNDS 15-CETO-PROSTAGLANDINA.
BG104062A (en) Treatment of diabetes with thiazolidindion, stimulant of insulin secretion and alpha-glucosidase inhibitor
IE46171L (en) N-pyrrolidinylmethylbenzamide derivative.
EA200000039A1 (en) TREATMENT OF DIABETES THIAZOLIDINDION AND SULPHONYL URIDE
BG104139A (en) Diabetes treatment with thizolidindion and sulphonylurea
MX9709958A (en) A method of reducing the amount of exogenous insulin administered to a patient having noninsulin-dependent diabetes mellitus.
KR920702676A (en) New stereoisomers